Merck & Company will purchase eye treatment maker, Inspire Pharmaceuticals, for $430 million, The Wall Street Journal reports. Private-equity company, Warburg Pincus, which owns about 28% of Inspire’s outstanding shares, will tender all of its shares to the offer.
The deal has received approval from the boards of both the companies. Merck will buy all remaining Inspire shares through a second-step merger after the tender offer closes.
Click here for the story from The Wall Street Journal.
Click here for the additional coverage from Reuters.